Organization (Nonprofit)
Oklahoma Medical Research Foundation
ClinicalTrials.gov lists Oklahoma Medical Research Foundation as lead sponsor of 14 trials. It has 2 active development programs and 7 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Oklahoma Medical Research Foundation: 14 lead-sponsored trials and 1 legal-entity registration.
Disease areas (14)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lupus Erythematosus, Systemic | 11 |
| Arthritis, Rheumatoid | 4 |
| Herpes Zoster | 2 |
| Multiple Sclerosis | 2 |
| Arthralgia | 1 |
Showing 5 of 14 disease areas.
Trials by start year as sponsor or collaborator (20)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2015 | 1 |
Showing 10 of 20 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (2)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| METFORMIN | Insulin Resistance | Phase 3 | 1 |
| Anifrolumab | Lupus Erythematosus, Systemic | Early 1 | 1 |
Approved assets (7)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Belimumab | 1 |
| METFORMIN | 1 |
| Certolizumab Pegol | 1 |
| Abatacept | 1 |
| METHYLPREDNISOLONE | 1 |
Showing 5 of 7 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 4 hit target (n=4) | 60% on time (n=5) |
Journals published in (42)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Arthritis and rheumatism | 10 |
| Genes and immunity | 5 |
| American journal of human genetics | 4 |
| Human genetics | 3 |
| The Journal of rheumatology | 3 |
Showing 5 of 42 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 207 | 14 | 2025-11-11 |
Financing and grant events (323)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-19 | NIH grant | 468,875 | Reporter |
| 2025-09-18 | NIH grant | 767,249 | Reporter |
| 2025-09-10 | NIH grant | 2,602,940 | Reporter |
| 2025-09-03 | NIH grant | 3,130,679 | Reporter |
| 2025-09-03 | NIH grant | 3,364,935 | Reporter |
Showing 5 of 323 events.
Organization relationships (20)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of California System | Co sponsors trial with | 2 |
| University of Birmingham | Co sponsors trial with | 1 |
| University Medical Center Groningen | Co sponsors trial with | 1 |
| University of Toronto | Co sponsors trial with | 1 |
| Roche (Switzerland) | Co sponsors trial with | 1 |
Showing 5 of 20 relationships.
Latest dated events (555)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-11 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-09-19 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-18 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 555 events.
CLIA clinical laboratory certificates (2)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| OKLAHOMA MEDICAL RESEARCH FOUNDATION | Certificate of waiver | Active |
| OKLAHOMA MEDICAL RESEARCH FOUNDATION | Certificate of waiver | Active |
Biomarker capability evidence (25)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| TNF | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial exclusion criteria |
| CD4 | Trial sponsor | Named in trial exclusion criteria |
| EGFR | Trial collaborator | Named in trial exclusion criteria |
| IL1RN | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 25 evidence rows.
Biomarkers this organization publishes on (382)
Shown in this order: most publications first.
Showing 5 of 382 biomarkers.
On Scientist.com
Oklahoma Medical Research Foundation is linked to 4 research suppliers in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.
Work with Oklahoma Medical Research Facility - BIACORE Core on Scientist.com
For prices, more details, or to contact Oklahoma Medical Research Facility - BIACORE Core, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.